Novartis Agrees to Acquire Avidity Biosciences
Novartis has entered into an agreement to acquire Avidity Biosciences, Inc., a biopharmaceutical company based in San Diego.
Avidity is focused on a new class of therapeutics enabling RNA delivery to muscle, specifically working on Antibody Oligonucleotide Conjugates (AOCs) for serious, genetic neuromuscular diseases.
The acquisition will bring Avidity’s late-stage neuroscience programs into Novartis, providing access to a differentiated RNA-targeting delivery platform, following the separation of Avidity’s early-stage precision cardiology programs.
No additional information is provided.
Author summary: Novartis acquires Avidity Biosciences.
More News
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- “A Nation Held Hostage by Crooks”: Professor Chirwa Tears Into Mutharika’s Chaotic Appointments, Says Malawi Is Being Looted Piece by Piece - Malawi Nyasa Times - News from Malawi about Malawi
- Honkarakenne Brings Finnish Timber Construction Expertise to Kazakhstan – Two New Memoranda of Understanding Signed to Advance Sustainable Tourism and Ecological Solutions
- Cisco and G42 Deepen US-UAE Technology Partnership to Build Secure, End-to-End AI Infrastructure in the UAE
- MLB: The Last 10 World Series MVPs
- Milei, the two Caputos and the two anchors
- From Rocks to Revenue: Malawi’s Minerals at a Crossroads - Malawi Nyasa Times - News from Malawi about Malawi
- At 25, Damu school still in shambles Malawi 24 | Latest News from Malawi
- DELLA-MATTIA: Caputo has right to personal opinion, social media page
- Power Shifts at the Top: Tambulasi Takes Over MRA, Mbeta Named Attorney General - Malawi Nyasa Times - News from Malawi about Malawi